Lung Cancer Canada Needs Your Help

[KatieB]

Seeking lung cancer patients who have taken or are taking osimertinib (Tagrisso) or pembrolizumab (Keytruda).

Lung Cancer Canada, the only Canadian national organization solely focused on lung cancer, is looking for NSCLC patients and caregivers who have experience with osimertinib (Tagrisso) or pemrolizumab (Keytruda).

After a drug receives approval from Health Canada, the Pan-Canadian Oncology Drug Review (pCODR) evaluates the drug and makes a recommendation on whether the drug should be publicly funded. PCODR considers both the clinical evidence and patient/caregiver experience in their decision.

Lung Cancer Canada is coordinating a submission to pCODR representing the patient voice and as such, is currently seeking patients and their caregivers, who have been on Tagrisso or Keytruda, either presently or in the past. Patients and caregivers would be asked to participate in a brief (30-60 mins) interview via teleconference to share their experience with this drug. You don’t have to be Canadian  and all personal information, including participant's identities, would be kept strictly confidential.

If you are interested in participating, contact Daniel Gillespie at dan@lungcancercanada.ca.